Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE® (afamelanotide) and the future of photomedicine. Over 70 guests discussed the Company’s unique history and future growth potential at an invitation-only event in Düsseldorf. Managing Director and CEO, Dr Philippe Wolgen shared the Company’s success in establishing profitability over the past seven financial years, bu...
>ROC de 46.3 M€ (vs 46.8 M€e) soit une marge de 10.8% (-10 pb) - Roche Bobois a publié ce matin des résultats annuels globalement en ligne avec nos attentes. Pour un CA (déjà publié) de 429.5 M€ en progression de 5.1%, l’EBITDA s’élève à 90.5 M€ (vs 87 M€e) et le ROC à 46.3 M€ (vs 46.8 M€e) soit une MOC de 10.8% en légère baisse de 10 pb. Le RNpg est quant à lui stable à 31.3 M€ (vs 32 M€e). Le groupe affiche une position de trésorerie nette, hors IFRS 16, de 30.6 M€ ...
Two Directors at OPT Machine Vision Tech Co Ltd bought 2,913 shares at between 94.350CNY and 96.510CNY. The significance rating of the trade was 35/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's dir...
A director at Hi-Trend Technology (Shanghai) Co Ltd bought 1,015 shares at 48.800CNY and the significance rating of the trade was 39/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the...
A director at Alpha Services and Holdings S.A sold 26,836 shares at 1.729EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...
A director at BRT Apartments Corp bought 22,214 shares at 16.244USD and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Two Directors at Summit Therapeutics Inc bought 210,321 shares at between 3.726USD and 3.750USD. The significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ...
Selling pressure ruled the trading and SOFIX (803.52, -0.12%) closed in red on Wednesday. Chimimport (CHIM, BGN 0.682, -3.13%), First Investment Bank (FIB, BGN 2.42, -1.63%) and Sopharma (SFA, BGN 6.24, -1.27%) fully offset the positive moves of Sirma Group Holding (SGH, BGN 0.75, +2.74%) and M+S Hydraulic (MSH, BGN 10.40, +1.96%). 1.76m shares of Gradus (GR6, BGN 1.70, +13.33%) lifted the company to daily top gainers’ place and pushed up BGTR30 (813.04, +0.53%) and BGBX40 (164.71, +0.31%).
Moody's Ratings ("Moody's") has assigned definitive Aaa (sf) ratings to two classes of floating rate notes issued by Shinhan Card 2024-1 International Ltd. The complete rating action is as follows: Issuer: Shinhan Card 2024-1 International Ltd ....U.S.$300,000,000 Class A1 Floating Rate Secured...
We have lowered our FY24 and FY25 adjusted EBITDA forecasts by respectively 25% and 21% following weaker than expected FY23 results and FY24 guidance. Tessenderlo is a very diversified group with limited synergies between the various operations. Valuation is clearly attractive and we expect the strong balance sheet will prompt the board to decide on an extension of the current share buyback program, allowing the company to benefit from the low share price to catch up additional stock. We maintai...
Moody's Ratings ("Moody's") has assigned definitive Aaa (sf) ratings to two classes of floating rate secured notes issued by KB Kookmin Card Thirteenth International Ltd. The complete rating action is as follows: Issuer: KB Kookmin Card Thirteenth International Ltd. ....U.S.$200,000,000 Class ...
>Pas de croissance du CA attendue pour le prochain exercice FY 25 - Soitec a confirmé hier soir la réalisation de ses guidances pour l’exercice FY 24 (clôture à fin mars) qui avaient été revues en baisse début février. Le CA devrait bien baisser d’environ 10% en organique avec une marge EBITDA en retrait de près de 1 point à 34%. La mauvaise nouvelle porte sur la stabilité du CA visée pour le prochain exercice FY 25, un niveau nettement en deçà des attentes (ODDO...
>Solid development in 2023 - Berentzen published its final 2023 operating results which were in line with prelims. released on 6 February, 2024. All key numbers were within the forecast ranges (Revenue € 182m - € 190m, EBITDA € 15.3m - € 16.3m, EBIT € 7m - € 8m). Revenue increased by 6.6% y-o-y to € 185.7m (ODDO BHFe: € 185.5m; cons: € 185.4m) and was entirely driven by price increases; unit sales were slightly lower than in the 2022 financial year. EBITDA declined by...
>FY 2023 results and FCF sharply up, first dividend of € 0.30 per share - VusionGroup (formerly SES-imagotag) published yesterday evening its 2023 results, which were up sharply, exceeded expectations. With previously reported revenues up 29% to € 802m, the margin on variable costs (MCV) came in at 25.2% (vs 24.6%e.), up 4.3bp thanks to improved component purchase prices, the EUR/USD exchange rate effect and the VAS mix (more recurring business). Despite a higher opex...
EQS-News: GRAMMER Aktiengesellschaft / Schlagwort(e): Jahresergebnis GRAMMER AG steigert Umsatz und Ergebnis im Geschäftsjahr 2023 und bestellt COO Guoqiang Li zum Vorstand 28.03.2024 / 09:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. GRAMMER AG steigert Umsatz und Ergebnis im Geschäftsjahr 2023 und bestellt COO Guoqiang Li zum Vorstand GRAMMER Gruppe steigert Umsatz um 6,8 % auf 2.304,9 Mio. EUR Free Cashflow steigt auf 48,2 Mio. EUR (Vj. 31,3 Mio. EUR) Operatives EBIT liegt mit 56,8 Mio. EUR ebenfalls deutlich über dem Vo...
EQS-News: GRAMMER Aktiengesellschaft / Key word(s): Annual Results GRAMMER increases revenue and earnings in FY 2023 and appoints COO Guoqiang Li to the Executive Board 28.03.2024 / 09:00 CET/CEST The issuer is solely responsible for the content of this announcement. GRAMMER increases revenue and earnings in FY 2023 and appoints COO Guoqiang Li to the Executive Board GRAMMER Group increases revenue by 6.8% to EUR 2,304.9 million Free cash flow climbs to EUR 48.2 million (previous year: EUR 31.3 million) Operating EBIT of EUR 56.8 million also clearly above previous ye...
>A good set of 2023 results with a marked improvement in profitability - Sidetrade has published solid 2023 results and a shade above forecasts. For sales (already published) of € 43.7m, up 19% (of which +15% org. on our calculations), the group has reported EBIT growth of 58% to € 5.8m (vs ODDO BHF at € 5.5m). This implies an operating margin of 13% (vs ODDO BHF at 12.5%), an improvement of +300bp vs N-1, with a solid performance in H2 (EBIT margin of around 14.5%). ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.